Literature DB >> 17318209

A robustness-based approach to systems-oriented drug design.

Hiroaki Kitano1.   

Abstract

Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.

Mesh:

Substances:

Year:  2007        PMID: 17318209     DOI: 10.1038/nrd2195

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  162 in total

1.  Effective models of periodically driven networks.

Authors:  Jason Shulman; Lars Seemann; Gemunu H Gunaratne
Journal:  Biophys J       Date:  2011-12-07       Impact factor: 4.033

Review 2.  The developmental genetics of biological robustness.

Authors:  Lamia Mestek Boukhibar; Michalis Barkoulas
Journal:  Ann Bot       Date:  2015-08-20       Impact factor: 4.357

Review 3.  Network-based approaches in drug discovery and early development.

Authors:  J M Harrold; M Ramanathan; D E Mager
Journal:  Clin Pharmacol Ther       Date:  2013-09-11       Impact factor: 6.875

4.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

5.  FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.

Authors:  Jo Ishizawa; Eiji Sugihara; Shinji Kuninaka; Kaoru Mogushi; Kensuke Kojima; Christopher B Benton; Ran Zhao; Dhruv Chachad; Norisato Hashimoto; Rodrigo O Jacamo; Yihua Qiu; Suk Young Yoo; Shinichiro Okamoto; Michael Andreeff; Steven M Kornblau; Hideyuki Saya
Journal:  Blood       Date:  2017-01-31       Impact factor: 22.113

Review 6.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

Review 7.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

Review 8.  Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds.

Authors:  Yan Feng; Timothy J Mitchison; Andreas Bender; Daniel W Young; John A Tallarico
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

Review 9.  Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.

Authors:  Chi-Ming Hai
Journal:  Curr Drug Discov Technol       Date:  2008-12

Review 10.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.